Overview of Interests
Dr. Conn is actively involved in studies to develop new treatment strategies for Fragile X syndrome and other childhood developmental disorders. This includes basic research aimed at identifying and validating new drug targets as well as drug discovery efforts aimed at advancing new drug candidates into clinical development with industry partners.
- Development of an M1 PAM Experimental Therapeutic fo Schizophrenia
- Functions of Metabotropic Glutamate Receptor Subtypes
- Muscarinic Receptor Activators as Antipsychotic Agents
- Regulation of Signaling by mGluR5
Back to the people index